Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update

Hookipa Pharma Inc (NASDAQ:HOOK) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 315,900 shares, a decline of 5.2% from the March 15th total of 333,400 shares. Based on an average trading volume of 562,100 shares, the short-interest ratio is currently 0.6 days. Approximately 0.5% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HOOK. Jane Street Group LLC acquired a new stake in Hookipa Pharma in the 4th quarter valued at about $43,000. Virtu Financial LLC acquired a new stake in shares of Hookipa Pharma in the second quarter valued at approximately $47,000. Two Sigma Investments LP bought a new position in Hookipa Pharma in the 3rd quarter worth approximately $51,000. Mirabella Financial Services LLP acquired a new position in Hookipa Pharma during the 1st quarter worth $82,000. Finally, Alyeska Investment Group L.P. bought a new position in Hookipa Pharma in the 4th quarter valued at $103,000. 63.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HOOK has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Hookipa Pharma in a report on Monday, March 25th. HC Wainwright reissued a “buy” rating and set a $6.50 price objective on shares of Hookipa Pharma in a report on Monday, March 25th.

Hookipa Pharma Trading Down 5.9 %

NASDAQ HOOK opened at $0.76 on Thursday. Hookipa Pharma has a 1-year low of $0.41 and a 1-year high of $2.05. The company has a 50 day moving average of $0.73 and a 200-day moving average of $0.65. The firm has a market cap of $75.45 million, a price-to-earnings ratio of -0.87 and a beta of 1.02.

Hookipa Pharma (NASDAQ:HOOK) last released its quarterly earnings results on Friday, March 22nd. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. The firm had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $3.60 million. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%. On average, analysts forecast that Hookipa Pharma will post -0.51 earnings per share for the current year.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.